These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
112 related articles for article (PubMed ID: 8069847)
1. Enhanced cell-mediated tumor killing in patients immunized with human monoclonal antiidiotypic antibody 105AD7. Durrant LG; Buckley TJ; Denton GW; Hardcastle JD; Sewell HF; Robins RA Cancer Res; 1994 Sep; 54(18):4837-40. PubMed ID: 8069847 [TBL] [Abstract][Full Text] [Related]
2. Clinical evidence that the human monoclonal anti-idiotypic antibody 105AD7, delays tumor growth by stimulating anti-tumor T-cell responses. Buckley DT; Robins AR; Durrant LG Hum Antibodies Hybridomas; 1995; 6(2):68-72. PubMed ID: 7492753 [TBL] [Abstract][Full Text] [Related]
3. A neoadjuvant clinical trial in colorectal cancer patients of the human anti-idiotypic antibody 105AD7, which mimics CD55. Durrant LG; Maxwell-Armstrong C; Buckley D; Amin S; Robins RA; Carmichael J; Scholefield JH Clin Cancer Res; 2000 Feb; 6(2):422-30. PubMed ID: 10690519 [TBL] [Abstract][Full Text] [Related]
4. Antitumor immune response and interleukin 2 production induced in colorectal cancer patients by immunization with human monoclonal anti-idiotypic antibody. Robins RA; Denton GW; Hardcastle JD; Austin EB; Baldwin RW; Durrant LG Cancer Res; 1991 Oct; 51(19):5425-9. PubMed ID: 1913661 [TBL] [Abstract][Full Text] [Related]
5. Cytotoxicity tests against cultured human lung cancer cells with autologous lymphocytes activated in vitro by mitomycin C-treated tumor monolayers in the presence of T-cell growth factor. Kimura H; Yamaguchi Y; Kadoyama C; Sato N; Fujisawa T Jpn J Clin Oncol; 1983 Mar; 13(1):3-13. PubMed ID: 6300483 [TBL] [Abstract][Full Text] [Related]
6. Re-targeting of cytotoxic T lymphocytes and/or natural killer cells to CEA-expressing tumor cells with anti-CEA antibody activity. Kuroki M; Hachimine K; Huang J; Shibaguchi H; Kinugasa T; Maekawa S; Kuroki M Anticancer Res; 2005; 25(6A):3725-32. PubMed ID: 16302732 [TBL] [Abstract][Full Text] [Related]
7. Enhancement of cell-mediated immunity in melanoma patients immunized with murine anti-idiotypic monoclonal antibodies (MELIMMUNE) that mimic the high molecular weight proteoglycan antigen. Pride MW; Shuey S; Grillo-Lopez A; Braslawsky G; Ross M; Legha SS; Eton O; Buzaid A; Ioannides C; Murray JL Clin Cancer Res; 1998 Oct; 4(10):2363-70. PubMed ID: 9796966 [TBL] [Abstract][Full Text] [Related]
8. Prognostic significance of circulating cytotoxic lymphocytes against autologous tumors in patients with bladder cancer. Mizutani Y; Okada Y; Terachi T; Yoshida O J Urol; 1996 Mar; 155(3):888-92; discussion 892-4. PubMed ID: 8583600 [TBL] [Abstract][Full Text] [Related]
9. Randomized double-blind phase II survival study comparing immunization with the anti-idiotypic monoclonal antibody 105AD7 against placebo in advanced colorectal cancer. Maxwell-Armstrong CA; Durrant LG; Buckley TJ; Scholefield JH; Robins RA; Fielding K; Monson JR; Guillou P; Calvert H; Carmichael J; Hardcastle JD Br J Cancer; 2001 Jun; 84(11):1443-6. PubMed ID: 11384090 [TBL] [Abstract][Full Text] [Related]
10. Tumor-draining lymph nodes of primary lung cancer patients: a potent source of tumor-specific killer cells and dendritic cells. Kimura H; Dobrenkov K; Iida T; Suzuki M; Ando S; Yamamoto N Anticancer Res; 2005; 25(1A):85-94. PubMed ID: 15816523 [TBL] [Abstract][Full Text] [Related]
11. A neoadjuvant/adjuvant randomized trial of colorectal cancer patients vaccinated with an anti-idiotypic antibody, 105AD7, mimicking CD55. Ullenhag GJ; Spendlove I; Watson NF; Indar AA; Dube M; Robins RA; Maxwell-Armstrong C; Scholefield JH; Durrant LG Clin Cancer Res; 2006 Dec; 12(24):7389-96. PubMed ID: 17121873 [TBL] [Abstract][Full Text] [Related]
12. In vitro induction of tumor-specific human lymphocyte antigen class I-restricted CD8 cytotoxic T lymphocytes by ovarian tumor antigen-pulsed autologous dendritic cells from patients with advanced ovarian cancer. Santin AD; Hermonat PL; Ravaggi A; Bellone S; Pecorelli S; Cannon MJ; Parham GP Am J Obstet Gynecol; 2000 Sep; 183(3):601-9. PubMed ID: 10992180 [TBL] [Abstract][Full Text] [Related]
13. VLA-6 (CDw49f) is an important adhesion molecule in NK cell-mediated cytotoxicity following autologous or allogeneic bone marrow transplantation. Lowdell MW; Shamim F; Hamon M; Macdonald ID; Prentice HG Exp Hematol; 1995 Dec; 23(14):1530-4. PubMed ID: 8542943 [TBL] [Abstract][Full Text] [Related]
14. Natural killer cell activity in tumor-draining lymph nodes: investigations in patients with malignant melanoma and head and neck cancer. Micksche M; Vinzenz K; Kokoschka EM; Kokoschka R Nat Immun Cell Growth Regul; 1985; 4(6):315-27. PubMed ID: 4088287 [TBL] [Abstract][Full Text] [Related]
15. Modulation of natural killer cell activity by serum from cancer patients: preliminary results of a study of patients with colorectal adenocarcinoma or other types of cancer. Pislarasu M; Oproiu A; Taranu D; Herberman RB; Sulica A Cancer Res; 1988 May; 48(9):2596-603. PubMed ID: 3356020 [TBL] [Abstract][Full Text] [Related]
16. Autologous tumor killing activity as a prognostic factor in primary resected nonsmall cell carcinoma of the lung. Fujisawa T; Yamaguchi Y Cancer; 1997 Feb; 79(3):474-81. PubMed ID: 9028357 [TBL] [Abstract][Full Text] [Related]
17. Sensitization of human bladder cancer cells to Fas-mediated cytotoxicity by cis-diamminedichloroplatinum (II). Mizutani Y; Yoshida O; Bonavida B J Urol; 1998 Aug; 160(2):561-70. PubMed ID: 9679929 [TBL] [Abstract][Full Text] [Related]
18. [Monoclonal anti-idiotype antibodies in immunotherapy of ovarian carcinoma (MAb ACA125) and breast carcinoma (MAb ACA14C5)]. Wagner U; Köhler S; Prietl G; Giffels P; Schmidt-Nicolai S; Schlebusch H; Grünn U; Bender H; Biersack HJ; De Potter C; Krebs D; Wallwiener D Zentralbl Gynakol; 1999; 121(4):190-5. PubMed ID: 10355096 [TBL] [Abstract][Full Text] [Related]
19. Expansion of natural killer cells in mice transgenic for IgM antibody to ganglioside GD2: demonstration of prolonged survival after challenge with syngeneic tumor cells. Kawashima I; Yoshida Y; Taya C; Shitara H; Yonekawa H; Karasuyama H; Tada N; Furukawa K; Tai T Int J Oncol; 2003 Aug; 23(2):381-8. PubMed ID: 12851687 [TBL] [Abstract][Full Text] [Related]
20. Anti-idiotype antibodies to the 9.1C3 blocking antibody used to probe the lethal hit stage of NK cell-mediated cytolysis. Werkmeister JA; Burns GF; Triglia T J Immunol; 1984 Sep; 133(3):1385-90. PubMed ID: 6611373 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]